ArticleNature communications2025
Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Programmable Self-Heating Microneedle Patch for on-Demand Postprandial Glucose Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug delivery and translational research · 2026Review
- In Vivo Continuous Biosensing: Design Considerations and Emerging Technologies.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Bioelectronic Considerations in Biomedical Microneedles.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Microneedle-Based Continuous Levodopa Monitoring in Patients with Parkinson's Disease.ACS sensors · 2026Article
- Wearable Electronics for Precision Diagnosis Through Advanced Manufacturing and Integration.Nano-micro letters · 2026Review
- 3D-printed chiral luminous materials.Nature communications · 2026Article
- Strain-isolated microneedles for ambulatory hormonal and metabolic monitoring.Nature nanotechnology · 2026Article
- Highly cited original research in microneedle science from 2015 to 2025 a bibliometric and altmetric analysis.Discover nano · 2026Review
- Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring and personalized care: a comprehensive review.Journal of materials science. Materials in medicine · 2026Review
- Fabrication and Evaluation of Rapidly Dissolving Microneedles Loaded with Organophosphorus Hydrolase for the Treatment of Transdermal Ethyl Paraoxon Poisoning.Pharmaceutics · 2026Article
- Enhancing Doxorubicin Bioavailability via Dissolving Microneedles: Roles of Drug Loading and Administration Force.AAPS PharmSciTech · 2026Article
- Biomarker-Guided Drug Delivery Systems and Oral Bioavailability Enhancement.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Materials and System Design for Self-Decision Bioelectronic Systems.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Evolution of 3D-Printed Microneedles toward Closed-Loop Theranostic Platforms.Research (Washington, D.C.) · 2026Review
- Integrating Polymeric 3D-Printed Microneedles with Wearable Devices: Toward Smart and Personalized Healthcare Solutions.Polymers · 2025Review
- Advances in 3D Printed Microneedles as a Prototype for Skin Targeted Therapeutics in Personalized Dermal Pharmaceuticals.AAPS PharmSciTech · 2025Review
- A Genetically Encoded Biosensor for Characterizing Transport and Metabolism of Glutarate.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microneedles in biomedicine: Innovations, challenges, and future prospects.Biomaterials translational · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision and personalized medicine for disease management necessitates real-time, continuous monitoring of biomarkers and therapeutic drugs to adjust treatment regimens based on individual patient responses. This study introduces a wearable Microneedle-based Continuous Biomarker/Drug Monitoring (MCBM) system, designed for the simultaneous, in vivo pharmacokinetic and pharmacodynamic evaluation for diabetes. Utilizing a dual-sensor microneedle and a layer-by-layer nanoenzyme immobilization strategy, the MCBM system achieves high sensitivity and specificity in measuring glucose and metformin concentrations in skin interstitial fluid (ISF). Seamless integration with a smartphone application enables real-time data analysis and feedback, fostering a pharmacologically informed approach to diabetes management. The MCBM system's validation and in vivo trials demonstrate its precise monitoring of glucose and metformin, offering a tool for personalized treatment adjustments. Its proven biocompatibility and safety suit long-term usage. This system advances personalized diabetes care, highlighting the move towards wearables that adjust drug dosages in real-time, enhancing precision and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.